SEC Company Response from Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — Apr 27, 2020
Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: April 27, 2020 · CIK: 0001006281 · Accession: 0001104659-20-051570
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237736
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Re: Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 Filed April 17, 2020 File No. 333-237736
Dear Mr. McCann:
We refer to the registration statement on Form S-3 (File No. 333-237736) (the “Registration Statement”) of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”). In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests the acceleration of the effectiveness of the Registration Statement so that it may become effective at 4:30 p.m. (Eastern time) on April 29, 2020 or as soon as practicable thereafter.
We thank you in advance for your time and attention to the Registration Statement. Should you wish to discuss the enclosed materials at any time, please do not hesitate to contact me at +972 (4) 902-8100 or Eyal.Rubin@protalix.com, or the Company’s counsel, Anna T. Pinedo of Mayer Brown LLP at +1 (212) 506-2275 or apinedo@mayerbrown.com.
Sincerely,
/s/ Eyal Rubin
Show Raw Text
CORRESP 1 filename1.htm April 27, 2020 VIA EDGAR Jeffrey Gabor Office of Life Sciences U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 Filed April 17, 2020 File No. 333-237736 Dear Mr. McCann: We refer to the registration statement on Form S-3 (File No. 333-237736) (the “Registration Statement”) of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”). In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests the acceleration of the effectiveness of the Registration Statement so that it may become effective at 4:30 p.m. (Eastern time) on April 29, 2020 or as soon as practicable thereafter. We thank you in advance for your time and attention to the Registration Statement. Should you wish to discuss the enclosed materials at any time, please do not hesitate to contact me at +972 (4) 902-8100 or Eyal.Rubin@protalix.com, or the Company’s counsel, Anna T. Pinedo of Mayer Brown LLP at +1 (212) 506-2275 or apinedo@mayerbrown.com. Sincerely, /s/ Eyal Rubin Eyal Rubin Sr. Vice President and Chief Financial Officer Protalix BioTherapeutics, Inc. cc: Dror Bashan Protalix BioTherapeutics, Inc. Anna T. Pinedo Mayer Brown LLP 2 Snunit Street, Science Park P.O.B. 455, Carmiel 20100, Israel Tel: 972-4-988-9488 | Fax: 972-4-988-9489 | Web: www.protalix.com